Education
About Us
Working with TipRanks
Follow Us
MedCap AB (DE:61MA)
FRANKFURT:61MA
61MA Stock Chart & Stats
€50.30
€0.90(1.70%)
At close: 4:00 PM EST
€50.30
€0.90(1.70%)
Day’s Range― - ―
52-Week Range€29.40 - €59.60
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€682.88M
Enterprise Value€7.43B
Total Cash (Recent Filing)€370.40M
Total Debt (Recent Filing)€707.00M
Price to Earnings (P/E)33.1
Beta0.11
Next Earnings
Apr 29, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding15,077,583
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue Scale-upSustained revenue growth from ~0.8B to ~2.1B (2020–2025) reflects successful deal-making and commercial expansion in niche healthcare markets. Durable top-line scale supports investment in product development, cross-selling across subsidiaries, and long-term margin and cashflow improvement.
Consistent Operating ProfitabilityMid-teens EBIT margins and ~10–11% net margins indicate structural profitability across operating subsidiaries. This persistent margin profile suggests defensible pricing or cost discipline in medical niches, enabling reinvestment and resilience to moderate demand swings over the medium term.
Positive And Growing Free Cash FlowConsistent positive FCF that has grown materially supports internal funding for capex, acquisitions, and upstreaming cash to the parent. While conversion is imperfect, multi-year positive FCF reduces reliance on external financing and underpins the buy-and-build investment model.
Bears Say
Increased Leverage In 2025A meaningful step-up in debt and debt-to-equity to ~0.49 reduces financial flexibility and raises servicing risk if earnings or cash flow weaken. For an acquisitive strategy, higher leverage limits optionality for further bolt-ons and elevates refinancing and interest-rate exposure over the medium term.
Uneven Cash ConversionRecurrent instances where OCF falls below reported earnings indicate working-capital swings or timing effects that weaken earnings quality. This unpredictability can strain liquidity in downturns, complicate dividend upstreaming, and reduce confidence in sustainable free cashflow projections.
2025 Gross-margin DeteriorationA sharp gross-margin decline in 2025 signals potential mix shifts, pricing pressure, or one-off cost items. If structural, this hurts profitability leverage and the group's ability to fund growth internally; persistent margin volatility undermines predictability of earnings and cash generation.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was €29.40 and its highest was €59.60 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is €682.88M.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 70 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported €0.455 earnings per share for the quarter, beating the consensus estimate of €0.447 by €0.008.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 0.44.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of €0.455 in its last earnings report, beating expectations of €0.447. Following the earnings report the stock price went up 8.994%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in DE:61MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---